Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital
Angélique Chauvineau‐Grenier, Paul Bastard, Antoine Servajean, et al.
Journal of Clinical Immunology (2022) Vol. 42, Iss. 3, pp. 459-470
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19
Evgeni Gusev, Alexey Sarapultsev, Л. В. Соломатина, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1716-1716
Open Access | Times Cited: 223
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
Jérémy Manry, Paul Bastard, Adrian Gervais, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 21
Open Access | Times Cited: 160
Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs
Stephanie Seneff, Greg Nigh, Anthony M. Kyriakopoulos, et al.
Food and Chemical Toxicology (2022) Vol. 164, pp. 113008-113008
Open Access | Times Cited: 151
From rare disorders of immunity to common determinants of infection: Following the mechanistic thread
Jean‐Laurent Casanova, Laurent Abel
Cell (2022) Vol. 185, Iss. 17, pp. 3086-3103
Open Access | Times Cited: 105
Human autoantibodies underlying infectious diseases
Anne Puel, Paul Bastard, Jacinta Bustamante, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 4
Open Access | Times Cited: 96
Autoantibodies against type I IFNs in patients with critical influenza pneumonia
Qian Zhang, Andrés Pizzorno, Lisa Miorin, et al.
The Journal of Experimental Medicine (2022) Vol. 219, Iss. 11
Open Access | Times Cited: 80
Type I interferons and SARS-CoV-2: from cells to organisms
Paul Bastard, Qian Zhang, Shen‐Ying Zhang, et al.
Current Opinion in Immunology (2022) Vol. 74, pp. 172-182
Open Access | Times Cited: 71
Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs
Jean‐Laurent Casanova, Mark S. Anderson
Journal of Clinical Investigation (2023) Vol. 133, Iss. 3
Open Access | Times Cited: 45
Human autoantibodies neutralizing type I IFNs: From 1981 to 2023
Paul Bastard, Adrian Gervais, Tom Le Voyer, et al.
Immunological Reviews (2024) Vol. 322, Iss. 1, pp. 98-112
Open Access | Times Cited: 28
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children
Paul Bastard, Adrian Gervais, Maki Taniguchi, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 2
Open Access | Times Cited: 24
The ouroboros of autoimmunity
Jean‐Laurent Casanova, Jessica N. Peel, Jean Donadieu, et al.
Nature Immunology (2024) Vol. 25, Iss. 5, pp. 743-754
Closed Access | Times Cited: 22
The role of B cells in COVID-19 infection and vaccination
Shiru Chen, Fei Guan, Fabio Candotti, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 64
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Paul Bastard, Sara E. Vazquez, Jamin Liu, et al.
Science Immunology (2022) Vol. 8, Iss. 90
Open Access | Times Cited: 62
Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α
Alexis Mathian, Paul Breillat, Karim Dorgham, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 12, pp. 1695-1703
Open Access | Times Cited: 61
Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19
Caspar I. van der Made, Mihai G. Netea, Frank L. van der Veerdonk, et al.
Genome Medicine (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 59
Interferon induction, evasion, and paradoxical roles during SARS‐CoV‐2 infection*
Carolina Chiale, Trever T. Greene, Elina I. Zúñiga
Immunological Reviews (2022) Vol. 309, Iss. 1, pp. 12-24
Open Access | Times Cited: 47
Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19
Shohei Eto, Yoko Nukui, Miyuki Tsumura, et al.
Journal of Clinical Immunology (2022) Vol. 42, Iss. 7, pp. 1360-1370
Open Access | Times Cited: 40
Interfering with Interferons: A Critical Mechanism for Critical COVID-19 Pneumonia
Helen C. Su, Huie Jing, Yu Zhang, et al.
Annual Review of Immunology (2023) Vol. 41, Iss. 1, pp. 561-585
Open Access | Times Cited: 34
Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility
Benjamin G. Hale
European Journal of Immunology (2023) Vol. 53, Iss. 6
Open Access | Times Cited: 28
Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia
Quentin Philippot, Arnaud Fekkar, Adrian Gervais, et al.
Journal of Clinical Immunology (2023) Vol. 43, Iss. 6, pp. 1093-1103
Open Access | Times Cited: 25
Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies
Sonja Fernbach, Nina K. Mair, Irène A. Abela, et al.
The Journal of Experimental Medicine (2024) Vol. 221, Iss. 9
Open Access | Times Cited: 11
Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
Aurélien Sokal, Paul Bastard, Pascal Chappert, et al.
The Journal of Experimental Medicine (2022) Vol. 220, Iss. 1
Open Access | Times Cited: 33
Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study
Romain Arrestier, Paul Bastard, Thibaut Belmondo, et al.
Annals of Intensive Care (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 29
Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis
Xi Wang, Qi Tang, Hongmei Li, et al.
International Journal of Infectious Diseases (2023) Vol. 130, pp. 147-152
Open Access | Times Cited: 17
Autoantibodies Neutralizing Type III Interferons Are Uncommon in Patients with Severe Coronavirus Disease 2019 Pneumonia
Martti Vanker, Karita Särekannu, Arnaud Fekkar, et al.
Journal of Interferon & Cytokine Research (2023) Vol. 43, Iss. 9, pp. 379-393
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top